A药品名称: B药品名称: B与A对换
 药物之间的相互作用1329045个记录(本栏目收费,不能展示细节,电话13136136841)
药物之间的相互作用
A药品
B药品
详细
Rolitetracycline
Ezogabine
The risk or severity of QTc prolongation can be increased when Ezogabine is combined with Dabrafenib.
Rolitetracycline
Farnesyl thiopyrophosphate
The risk or severity of QTc prolongation can be increased when Farnesyl thiopyrophosphate is combined with Dabrafenib.
Rolitetracycline
Fleroxacin
The risk or severity of QTc prolongation can be increased when Fleroxacin is combined with Dabrafenib.
Rolitetracycline
Vorinostat
The risk or severity of QTc prolongation can be increased when Vorinostat is combined with Dabrafenib.
Rolitetracycline
Pheniramine
The risk or severity of QTc prolongation can be increased when Pheniramine is combined with Dabrafenib.
Rolitetracycline
Ajmaline
The risk or severity of QTc prolongation can be increased when Ajmaline is combined with Dabrafenib.
Rolitetracycline
Methotrimeprazine
The risk or severity of QTc prolongation can be increased when Methotrimeprazine is combined with Dabrafenib.
Rolitetracycline
Fostemsavir
Dabrafenib may decrease the excretion rate of Fostemsavir which could result in a higher serum level.
Rolitetracycline
Lusutrombopag
Dabrafenib may decrease the excretion rate of Lusutrombopag which could result in a higher serum level.
Rolitetracycline
Paritaprevir
Paritaprevir may decrease the excretion rate of Dabrafenib which could result in a higher serum level.
Rolitetracycline
Delafloxacin
Dabrafenib may decrease the excretion rate of Delafloxacin which could result in a higher serum level.
Rolitetracycline
Ertugliflozin
Dabrafenib may decrease the excretion rate of Ertugliflozin which could result in a higher serum level.
Rolitetracycline
Talazoparib
Dabrafenib may decrease the excretion rate of Talazoparib which could result in a higher serum level.
Rolitetracycline
Fimasartan
Dabrafenib may decrease the excretion rate of Fimasartan which could result in a higher serum level.
Rolitetracycline
Sofosbuvir
Dabrafenib may decrease the excretion rate of Sofosbuvir which could result in a higher serum level.
Rolitetracycline
Dolutegravir
Dabrafenib may decrease the excretion rate of Dolutegravir which could result in a higher serum level.
Rolitetracycline
Isavuconazole
The serum concentration of Dabrafenib can be increased when it is combined with Isavuconazole.
Rolitetracycline
Pitolisant
The serum concentration of Dabrafenib can be decreased when it is combined with Pitolisant.
Rolitetracycline
Delamanid
Dabrafenib may increase the QTc-prolonging activities of Delamanid.
Rolitetracycline
Apalutamide
The serum concentration of Apalutamide can be increased when it is combined with Dabrafenib.
免责声明:以上所展示的信息由企业自行提供,内容的真实性、准确性和合法性由发布企业负责,医药网对此不承担任何责任。
相关链接:医药研究数据| 医药资料| SDA药品评审中心| 中医网| 中药处方系统| 爱视立眼贴
专业提供药品信息、药品招商、药品代理、保健品招商、医药原料采购供应的中国药品信息网站平台
版权所有 © 2003-2028 盗冒必究  客服热线:0575-83552251 / 13754370441  QQ客服:药品信息客服
浙ICP备16010490号-2 增值电信业务经营许可证:浙B2-20220931 互联网药品信息服务资格证书编号:(浙)-经营性2023-0215 浙公网安备:330683240604819103159
 医药代理商群1:药药网药品采购交流医药代理商群2:药药网药品采购交流2医药代理商群3:药药网药品采购交流3